Additional file 1 of A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma

Authors :: Booth, Stephen W.
Eyre, Toby A.
Whittaker, John
Campo, Leticia
Wang, Lai Mun
Soilleux, Elizabeth
Royston, Daniel
Rees, Gabrielle
Kesavan, Murali
Hildyard, Catherine
Kazmi, Farasat
La Thangue, Nick
Kerr, David
Middleton, Mark R.
Collins, Graham P.
Publication Year :: 2021
Publisher :: figshare, 2021.
Abstract: Additional file 1: Table S1. All treatment emergent adverse events categorised and graded according to CTCAE version 4.03. Table S2. HR23B score data for all treated patients. Figure S1. Progression-free Survival on CXD101.

Full Text Access

Tools